Zhen-peng Guan

Dr. Zhen-peng Guan


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
ZWZhen Wang
Zhen Wang
YWYichuan Wang
Yichuan Wang
JYJiaqi Yan
Jiaqi Yan
KZKeshi Zhang
Keshi Zhang
FLFeng Lin
Feng Lin
Hongbo ZhangHongbo Zhang
Hongbo Zhang
Bone regenerative engineering provides a great platform for bone tissue regeneration covering cells, growth factors and other dynamic forces for fabricating scaffolds. Diversified biomaterials and their fabrication methods have emerged for fabricating patient specific bioactive scaffolds with controlled microstructures for bridging complex bone defects. The goal of this review is to summarize the points of scaffold design as well as applications for bone regeneration based on both electrospinning and 3D bioprinting. It first briefly introduces biological characteristics of bone regeneration and summarizes the applications of different types of material and the considerations for bone regeneration including polymers, ceramics, metals and composites. We then discuss electrospinning nanofibrous scaffold applied for the bone regenerative engineering with various properties, components and structures. Meanwhile, diverse design in the 3D bioprinting scaffolds for osteogenesis especially in the role of drug and bioactive factors delivery are assembled. Finally, we discuss challenges and future prospects in the development of electrospinning and 3D bioprinting for osteogenesis and prominent strategies and directions in future.

12 June 2021 in Bioactive Materials
Verified
Journal Article
Open access
WYWei Yuan
Wei Yuan
DXDandan Xia
Dandan Xia
SWShuilin Wu
Shuilin Wu
Yufeng ZhengYufeng Zheng
Yufeng Zheng
ZGZhen-peng Guan
Zhen-peng Guan
Julietta V. RauJulietta V. Rau
Julietta V. Rau
Recently, zinc and its alloys have been proposed as promising candidates for biodegradable metals (BMs), owning to their preferable corrosion behavior and acceptable biocompatibility in cardiovascular, bone and gastrointestinal environments, together with Mg-based and Fe-based BMs. However, there is the desire for surface treatment for Zn-based BMs to better control their biodegradation behavior. Firstly, the implantation of some Zn-based BMs in cardiovascular environment exhibited intimal activation with mild inflammation. Secondly, for orthopedic applications, the biodegradation rates of Zn-based BMs are relatively slow, resulting in a long-term retention after fulfilling their mission. Meanwhile, excessive Zn2+ release during degradation will cause in vitro cytotoxicity and in vivo delayed osseointegration. In this review, we firstly summarized the current surface modification methods of Zn-based alloys for the industrial applications. Then we comprehensively summarized the recent progress of biomedical bulk Zn-based BMs as well as the corresponding surface modification strategies. Last but not least, the future perspectives towards the design of surface bio-functionalized coatings on Zn-based BMs for orthopedic and cardiovascular applications were also briefly proposed.

1 July 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
PXPan Xiong
Pan Xiong
ZJZhaojun Jia
Zhaojun Jia
WZWenhao Zhou
Wenhao Zhou
JYJianglong Yan
Jianglong Yan
PWPei Wang
Pei Wang
Yufeng ZhengYufeng Zheng
Yufeng Zheng

1 June 2020 in The Lancet
Verified
Journal Article
Closed access
CTChong Tang
Chong Tang
YWYichuan Wang
Yichuan Wang
HLHoushan Lv
Houshan Lv
ZGZhen-peng Guan
Zhen-peng Guan
JGJin Gu
Jin Gu

11 August 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
ZLZhao Li
Zhao Li
BYBo Yuan
Bo Yuan
ZPZheng Pei
Zheng Pei
KZKeshi Zhang
Keshi Zhang
ZDZhentao Ding
Zhentao Ding
YCYongping Cao
Yongping Cao
Osteoarthritis (OA) is a prevalent degenerative joint disease whose pathogenesis remains unclear. The research aims to investigate the roles of Circ_0136474/miR‐127‐5p/MMP‐13 axis in OA. Differentially expressed circRNAs and miRNAs in OA cartilage tissue were screened out and visualized by R project based on RNA‐seq data and microarray data respectively. qRT‐PCR was carried out for detection of relative expression levels of Circ_0136474, miR‐127‐5p, MMP‐13 and other inflammatory factors and Western blot analysis was conducted to detect the protein expression level of MMP‐13. CCK‐8 assay and flow cytometry were conducted to determine cell proliferation and cell apoptotic ability respectively. RNA‐fluorescence in situ hybridization (RNA‐FISH) experiments were conducted to confirm the immune‐localization of the Circ_0136474 and MMP‐13 in human tissues. Targeted relationships were predicted by bioinformatic analysis and verified by dual‐luciferase reporter assay. Our findings revealed that the expression levels of both Circ_0136474 and MMP‐13 in OA cartilage tissue were significantly higher than that in normal cartilage tissue. Circ_0136474 could suppress cell proliferation by facilitating MMP‐13 expression and suppressing miR‐127‐5p expression in OA. Overexpression of miR‐127‐5p negatively regulated MMP‐13 expression to enhance cell proliferation. Our study demonstrated that Circ_0136474 and MMP‐13 suppressed cell proliferation, while enhanced cell apoptosis by competitive binding to miR‐127‐5p in OA, which may well provide us with a new therapeutic strategy for osteoarthritis.

25 June 2021 in Small
Verified
Journal Article
Open access
PDF file
JYJiaqi Yan
Jiaqi Yan
YWYichuan Wang
Yichuan Wang
MRMeixin Ran
Meixin Ran
RMRawand A. Mustafa
Rawand A. Mustafa
HLHuanhuan Luo
Huanhuan Luo
Hongbo ZhangHongbo Zhang
Hongbo Zhang
Local minimally invasive injection of anticancer therapies is a compelling approach to maximize the utilization of drugs and reduce the systemic adverse drug effects. However, the clinical translation is still hampered by many challenges such as short residence time of therapeutic agents and the difficulty in achieving multi‐modulation combination therapy. Herein, mesoporous silica‐coated gold nanorods (AuNR@SiO2) core‐shell nanoparticles are fabricated to facilitate drug loading while rendering them photothermally responsive. Subsequently, AuNR@SiO2 is anchored into a monodisperse photocrosslinkable gelatin (GelMA) microgel through one‐step microfluidic technology. Chemotherapeutic drug doxorubicin (DOX) is loaded into AuNR@SiO2 and 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA) is loaded in the microgel layer. The osteosarcoma targeting ligand alendronate is conjugated to AuNR@SiO2 to improve the tumor targeting. The microgel greatly improves the injectability since they can be dispersed in buffer and the injectability and degradability are adjustable by microfluidics during the fabrication. The drug release can, in turn, be modulated by multi‐round light‐trigger. Importantly, a single super low drug dose (1 mg kg−1 DOX with 5 mg kg−1 DMXAA) with peritumoral injection generates long‐term therapeutic effect and significantly inhibited tumor growth in osteosarcoma bearing mice. Therefore, this nanocomposite@microgel system can act as a peritumoral reservoir for long‐term effective osteosarcoma treatment.